Effect of estrogen on coronary vasoconstriction in patients undergoing coronary angioplasty

Tsung-Ming Lee, Tsai Fwu Chou, Chang Her Tsai

Research output: Contribution to journalArticle

Abstract

Background: Estrogen has an antioxidant potential which may contribute to its cardioprotective effect. We sought to determine whether estrogen administration can affect coronary vasomotor tone in patients after angioplasty by reducing 8-iso-prostaglandin (PG) F concentrations, a bioactive product of lipid peroxidation. Methods: The study was designed to prospectively investigate 30 consecutive patients scheduled for elective coronary angioplasty. Patients were randomized into two groups according to whether they did not (group 1, n=15) or did have (group 2, n=15) intracoronary (i.c.) treatment with estrogen prior to coronary angioplasty. Results: There were no significant differences of collateral circulation assessed by intracoronary Doppler flow velocity during balloon inflations between the study groups. The diameters of the coronary artery at the dilated and distal segments were significantly reduced 15 min after dilation compared with those immediately after dilation in group 1 (both P2α levels in plasma from the coronary sinus rose significantly from 194±45 to 390±97 pg/ml (P2α levels in group 1 (r=0.73, P=0.002). Conclusions: 8-iso-PGF is released into the coronary circulation during angioplasty, and this vasoactive substance may contribute to the occurrence of vasoconstriction. Estrogen administration attenuated vasoconstriction by reducing the 8-iso-PGF levels. This finding may provide a new strategy to treat coronary vasoconstriction after angioplasty.

Original languageEnglish
Pages (from-to)465-472
Number of pages8
JournalInternational Journal of Cardiology
Volume101
Issue number3
DOIs
Publication statusPublished - Jun 8 2005

Fingerprint

Vasoconstriction
Angioplasty
Estrogens
Dinoprost
Dilatation
Coronary Circulation
Collateral Circulation
Coronary Sinus
Economic Inflation
Lipid Peroxidation
Coronary Vessels
Antioxidants
Therapeutics

Keywords

  • 8-iso-PGF
  • Coronary angioplasty
  • Estrogen
  • Vasoconstriction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of estrogen on coronary vasoconstriction in patients undergoing coronary angioplasty. / Lee, Tsung-Ming; Chou, Tsai Fwu; Tsai, Chang Her.

In: International Journal of Cardiology, Vol. 101, No. 3, 08.06.2005, p. 465-472.

Research output: Contribution to journalArticle

Lee, Tsung-Ming ; Chou, Tsai Fwu ; Tsai, Chang Her. / Effect of estrogen on coronary vasoconstriction in patients undergoing coronary angioplasty. In: International Journal of Cardiology. 2005 ; Vol. 101, No. 3. pp. 465-472.
@article{dcb341c20fa74ae3ae8389df4477162b,
title = "Effect of estrogen on coronary vasoconstriction in patients undergoing coronary angioplasty",
abstract = "Background: Estrogen has an antioxidant potential which may contribute to its cardioprotective effect. We sought to determine whether estrogen administration can affect coronary vasomotor tone in patients after angioplasty by reducing 8-iso-prostaglandin (PG) F2α concentrations, a bioactive product of lipid peroxidation. Methods: The study was designed to prospectively investigate 30 consecutive patients scheduled for elective coronary angioplasty. Patients were randomized into two groups according to whether they did not (group 1, n=15) or did have (group 2, n=15) intracoronary (i.c.) treatment with estrogen prior to coronary angioplasty. Results: There were no significant differences of collateral circulation assessed by intracoronary Doppler flow velocity during balloon inflations between the study groups. The diameters of the coronary artery at the dilated and distal segments were significantly reduced 15 min after dilation compared with those immediately after dilation in group 1 (both P2α levels in plasma from the coronary sinus rose significantly from 194±45 to 390±97 pg/ml (P2α levels in group 1 (r=0.73, P=0.002). Conclusions: 8-iso-PGF2α is released into the coronary circulation during angioplasty, and this vasoactive substance may contribute to the occurrence of vasoconstriction. Estrogen administration attenuated vasoconstriction by reducing the 8-iso-PGF2α levels. This finding may provide a new strategy to treat coronary vasoconstriction after angioplasty.",
keywords = "8-iso-PGF, Coronary angioplasty, Estrogen, Vasoconstriction",
author = "Tsung-Ming Lee and Chou, {Tsai Fwu} and Tsai, {Chang Her}",
year = "2005",
month = "6",
day = "8",
doi = "10.1016/j.ijcard.2004.05.044",
language = "English",
volume = "101",
pages = "465--472",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Effect of estrogen on coronary vasoconstriction in patients undergoing coronary angioplasty

AU - Lee, Tsung-Ming

AU - Chou, Tsai Fwu

AU - Tsai, Chang Her

PY - 2005/6/8

Y1 - 2005/6/8

N2 - Background: Estrogen has an antioxidant potential which may contribute to its cardioprotective effect. We sought to determine whether estrogen administration can affect coronary vasomotor tone in patients after angioplasty by reducing 8-iso-prostaglandin (PG) F2α concentrations, a bioactive product of lipid peroxidation. Methods: The study was designed to prospectively investigate 30 consecutive patients scheduled for elective coronary angioplasty. Patients were randomized into two groups according to whether they did not (group 1, n=15) or did have (group 2, n=15) intracoronary (i.c.) treatment with estrogen prior to coronary angioplasty. Results: There were no significant differences of collateral circulation assessed by intracoronary Doppler flow velocity during balloon inflations between the study groups. The diameters of the coronary artery at the dilated and distal segments were significantly reduced 15 min after dilation compared with those immediately after dilation in group 1 (both P2α levels in plasma from the coronary sinus rose significantly from 194±45 to 390±97 pg/ml (P2α levels in group 1 (r=0.73, P=0.002). Conclusions: 8-iso-PGF2α is released into the coronary circulation during angioplasty, and this vasoactive substance may contribute to the occurrence of vasoconstriction. Estrogen administration attenuated vasoconstriction by reducing the 8-iso-PGF2α levels. This finding may provide a new strategy to treat coronary vasoconstriction after angioplasty.

AB - Background: Estrogen has an antioxidant potential which may contribute to its cardioprotective effect. We sought to determine whether estrogen administration can affect coronary vasomotor tone in patients after angioplasty by reducing 8-iso-prostaglandin (PG) F2α concentrations, a bioactive product of lipid peroxidation. Methods: The study was designed to prospectively investigate 30 consecutive patients scheduled for elective coronary angioplasty. Patients were randomized into two groups according to whether they did not (group 1, n=15) or did have (group 2, n=15) intracoronary (i.c.) treatment with estrogen prior to coronary angioplasty. Results: There were no significant differences of collateral circulation assessed by intracoronary Doppler flow velocity during balloon inflations between the study groups. The diameters of the coronary artery at the dilated and distal segments were significantly reduced 15 min after dilation compared with those immediately after dilation in group 1 (both P2α levels in plasma from the coronary sinus rose significantly from 194±45 to 390±97 pg/ml (P2α levels in group 1 (r=0.73, P=0.002). Conclusions: 8-iso-PGF2α is released into the coronary circulation during angioplasty, and this vasoactive substance may contribute to the occurrence of vasoconstriction. Estrogen administration attenuated vasoconstriction by reducing the 8-iso-PGF2α levels. This finding may provide a new strategy to treat coronary vasoconstriction after angioplasty.

KW - 8-iso-PGF

KW - Coronary angioplasty

KW - Estrogen

KW - Vasoconstriction

UR - http://www.scopus.com/inward/record.url?scp=19344362083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19344362083&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2004.05.044

DO - 10.1016/j.ijcard.2004.05.044

M3 - Article

C2 - 15907416

AN - SCOPUS:19344362083

VL - 101

SP - 465

EP - 472

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -